STOCK MARKET BSE NSE

Malaria drug: Is it too much hype?

The government also said that these medications are presently not recommended for children less than 12 years, pregnant and lactating women.

Published: 07th April 2020 02:25 AM  |   Last Updated: 07th April 2020 10:09 AM   |  A+A-

Medical staff shows on February 26, 2020 at the IHU Mediterranee Infection Institute in Marseille, a packet of Nivaquine, tablets containing chloroquine, a commonly used malaria drug that has shown signs of effectiveness against coronavirus, according to a study conducted in several Chinese hospitals. (Photo | AFP)

Express News Service

NEW DELHI:  Anti-malaria drug Hydroxychloroquine seems to be emerging as medicine of choice for treating Covid-19 patients, in the absence of a more targeted treatment yet, but there is little empirical evidence to conclude it works in patients afflicted with novel coronavirus. The renewed focus on the drug comes after US President Donald Trump in a telephonic conversation with PM Narendra Modi reportedly asked him to remove the export ban on Hydroxychloroquine — a day after India, its biggest manufacturer — declared it won’t send the medicine outside.

In India, the drug along with antibiotic Azithromycin was recently included in the clinical management guideline for Covid-19 patients — replacing anti-HIV drugs Lopinavir, Ritonavir— by the Health Ministry and the Indian Council of Medical Research with the rider that the two drugs should be given only those needing ICU care. “These drugs should be administered under close medical supervision, with monitoring for side effects, including QTc interval,” the guidelines said as the drug may cause cardio-toxicity.

The government also said that these medications are presently not recommended for children less than 12 years, pregnant and lactating women. “These guidelines are based on currently available information,” the ministry said.  Sources said the revision had come as a study in the New England Journal said that the anti-HIV drug combination did not work in 199 patients analysed while another study from France said that the anti-malarial and antibiotic combination helped 78 out of 80 patients analysed.

There was another independent study from China to support Hydroxychloroquine-Azithromycin combination.  “The government says the drug, along with Azithromycin should be given to severely ill patients and also asks certain high-risk groups to use it prophylactically— it’s contradictory,” said Dr Anupam Singh, an infectious disease expert. 

Stay up to date on all the latest Nation news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp